

# Bacterial Pneumonia Market - 2022-2030

<https://marketpublishers.com/r/BADA2BDD0BB6EN.html>

Date: November 2025

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: BADA2BDD0BB6EN

## Abstracts

The Bacterial Pneumonia Market was valued at US\$ 2.7 billion in 2022 and is anticipated to reach US\$ 5.0 billion by 2030, at a CAGR of 0.081 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Bacterial Pneumonia Market.

This report delivers a comprehensive overview of the Bacterial Pneumonia Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bacterial Pneumonia Market. The Bacterial Pneumonia Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

Bacterial Pneumonia Market Scope:

By Type

Community-Acquired Pneumonia (CAP)

Hospital-Acquired Pneumonia (HAP)

By Route of Administration

Oral

Subcutaneous

Other

By Treatments

Vaccines

Drugs

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players

Innoviva Inc.

Pfizer Inc.

Merck & Co., Inc.

Melinta Therapeutics LLC

Evopoint Biosciences

Aridis Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

Eagle Pharmaceuticals, Inc.

Clarametyx Biosciences

Basilea Pharmaceutica Ltd

## Major Highlights

This report delivers a comprehensive overview of the Bacterial Pneumonia Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bacterial Pneumonia Market. The Bacterial Pneumonia Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the

latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Snippet by Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Treatments
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region

### **4. DYNAMICS**

- 4.1. Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. The Growing Number of Novel Product Launches
    - 4.1.1.2. Rising Prevalence of Bacterial Pneumonia
  - 4.1.2. Restraints
    - 4.1.2.1. Side Effects Associated with the Treatments
  - 4.1.3. Opportunity
    - 4.1.3.1. Rising Collaboration by Key Players or Several Organizations
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of COVID-19

- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

## **7. BY TYPE**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  - 7.1.2. Market Attractiveness Index, By Type
- 7.2. Community-Acquired Pneumonia (CAP) \*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Hospital-Acquired Pneumonia (HAP)
  - 7.3.1. Ventilator-associated pneumonia (VAP)
  - 7.3.2. Healthcare-associated pneumonia (HCAP)

## **8. BY ROUTE OF ADMINISTRATION**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Oral \*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Subcutaneous
- 8.4. Other

## **9. BY TREATMENTS**

- 9.1. Introduction
  - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
  - 9.1.2. Market Attractiveness Index, By Treatments
- 9.2. Vaccines \*

- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.2.3. Pneumococcal Conjugate Vaccines
- 9.2.4. Pneumococcal Polysaccharide Vaccine
- 9.3. Drugs
  - 9.3.1. Fluoroquinolones
    - 9.3.1.1. Ciprofloxacin
    - 9.3.1.2. Delafloxacin
    - 9.3.1.3. Gemifloxacin
    - 9.3.1.4. Levofloxacin
  - 9.3.2. Monobactams
    - 9.3.2.1. Azactam
    - 9.3.2.2. Aztreonam
  - 9.3.3. Tetracyclines
    - 9.3.3.1. Doxycycline
    - 9.3.3.2. Chlortetracycline
    - 9.3.3.3. Oxytetracycline
  - 9.3.4. Macrolides
    - 9.3.4.1. Azithromycin
    - 9.3.4.2. Clarithromycin
    - 9.3.4.3. Erythromycin
  - 9.3.5. Carbapenems
    - 9.3.5.1. Doripenem
    - 9.3.5.2. Ertapenem
  - 9.3.6. Antibiotics
    - 9.3.6.1. Lincomycin
    - 9.3.6.2. Pirlimycin
    - 9.3.6.3. Clindamycin

## **10. BY DISTRIBUTION CHANNEL**

- 10.1. Introduction
  - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  - 10.1.2. Market Attractiveness Index, By Distribution Channel
- 10.2. Hospital Pharmacies \*
  - 10.2.1. Introduction
  - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Retail Pharmacies
- 10.4. Online Pharmacies

## 11. BY REGION

### 11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

### 11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

### 11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments

11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.3.7.1. Germany

11.3.7.2. U.K.

11.3.7.3. France

11.3.7.4. Spain

11.3.7.5. Italy

11.3.7.6. Rest of Europe

### 11.4. South America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
  - 11.5.1. Introduction
  - 11.5.2. Key Region-Specific Dynamics
  - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
  - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  - 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.5.7.1. China
    - 11.5.7.2. India
    - 11.5.7.3. Japan
    - 11.5.7.4. Australia
    - 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
  - 11.6.1. Introduction
  - 11.6.2. Key Region-Specific Dynamics
  - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatments
  - 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

## **12. COMPETITIVE LANDSCAPE**

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

## **13. COMPANY PROFILES**

- 13.1. Innoviva Inc. \*
  - 13.1.1. Company Overview

- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Pfizer Inc.
- 13.3. Merck & Co., Inc.
- 13.4. Melinta Therapeutics LLC
- 13.5. Evopoint Biosciences
- 13.6. Aridis Pharmaceuticals Inc.
- 13.7. Cumberland Pharmaceuticals Inc.
- 13.8. Eagle Pharmaceuticals, Inc.
- 13.9. Clarametyx Biosciences
- 13.10. Basilea Pharmaceutica Ltd (\*LIST NOT EXHAUSTIVE)

## **14. APPENDIX**

- 14.1. About Us and Services
- 14.2. Contact Us

## I would like to order

Product name: Bacterial Pneumonia Market - 2022-2030

Product link: <https://marketpublishers.com/r/BADA2BDD0BB6EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BADA2BDD0BB6EN.html>